Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
51 hedge funds and large institutions have $6.08M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 21 reducing their positions, and 17 closing their positions.
1.91% less ownership
Funds ownership: 46.93% → 45.02% (-1.9%)
23% less funds holding
Funds holding: 66 → 51 (-15)
52% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 21
58% less capital invested
Capital invested by funds: $14.6M → $6.08M (-$8.56M)
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$1.07M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$47K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$7.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$737K |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$147K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$114K |
| 4 |
JP Morgan Chase
New York
|
-$90.7K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$67K |
EIGR Hedge Fund Activity: Q3 2023 in Review
51 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2023, worth a combined $6.08M — down 58% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EIGR and 2 opened new positions — a net loss of 15 holders — while 21 trimmed existing stakes and 10 added.
The largest buyer was Simplify Asset Management, adding an estimated $1.07M. The largest seller was 683 Capital Management, cutting an estimated $737K.
- 51 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2023, down from 66 in Q2 2023.
- Funds reported $6.08M of Eiger BioPharmaceuticals, Inc. stock for Q3 2023, down 58% quarter-over-quarter.
- 2 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2023 and 17 closed out, a net change of -15 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2023 was Simplify Asset Management, an estimated $1.07M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2023 was 683 Capital Management, an estimated $737K sold.
Based on aggregated 13F filings for Q3 2023.